FDA Panel Showdown Coming Over Epidural Steroid Injection Safety
This article was originally published in The Pink Sheet Daily
Executive Summary
Millions of epidural steroid injections are done off label for pain every year in America, but in some cases at the cost of paralysis, stroke or even death; FDA’s Anesthetic and Analgesic Drug Products Advisory Committee will consider labeling changes on Nov. 25.
You may also be interested in...
Outpatient Rx Safety Meeting To Spotlight Health Literacy, Provider Communication
US FDA has made efforts to improve health communications to cater to deficiencies in literacy; other specific topics for discussion at the meeting remain unclear.
FDA’s Compounding Oversight: What Price Safety?
As meningitis outbreak widens, FDA and members of Congress are calling for clarification of what jurisdiction the agency has over pharmacies, but agency officials are stopping short of asking for clear new authorities.
Rare Disease Roundtable: Dealing With Pricing Pressure
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.